KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Debt (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Total Debt data on record, last reported at $372.2 million in Q4 2025.

  • For Q4 2025, Total Debt fell 36.41% year-over-year to $372.2 million; the TTM value through Dec 2025 reached $372.2 million, down 36.41%, while the annual FY2025 figure was $372.2 million, 36.41% down from the prior year.
  • Total Debt reached $372.2 million in Q4 2025 per PCRX's latest filing, down from $376.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $585.3 million in Q4 2024 and bottomed at $109.8 million in Q2 2024.
  • Average Total Debt over 5 years is $257.1 million, with a median of $275.6 million recorded in 2022.
  • Peak YoY movement for Total Debt: crashed 65.68% in 2023, then surged 372.63% in 2024.
  • A 5-year view of Total Debt shows it stood at $359.5 million in 2021, then tumbled by 30.16% to $251.1 million in 2022, then tumbled by 50.67% to $123.8 million in 2023, then skyrocketed by 372.63% to $585.3 million in 2024, then crashed by 36.41% to $372.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $372.2 million in Q4 2025, $376.7 million in Q3 2025, and $300.2 million in Q2 2025.